

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

November 23, 2016

<p>To <b>National Stock Exchange of India Limited</b> Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051</p> <p><b>Stock Code: CADILAHC</b></p>	<p>To <b>Bombay Stock Exchange of India Limited</b> 1<sup>st</sup> Floor, Rotunda Building, Dalal Street, Mumbai – 400 001</p> <p><b>Stock Code: 532321</b></p>
<p>Kind Attention: Mr. Jiten Patel Assistant Manager [Listing]</p>	<p>Kind Attention: Ms. Dhara Barot Assistant Manager [Listing]</p>

Regarding: Clarification under Regulation 30 of SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015 [LODR] on news item – “Vietnam blacklists 39 Indian drug Companies for violation of standards”.

Dear Sirs,

We acknowledge the receipt of your mails with respect to media report in the Economic Times of today's edition titled – “Vietnam Bans 39 Indian Drug Cos for violating Quality Standards” and requesting / advising Company to provide clarification / confirmation.

We state and clarify as under:


“The Company recalled [Rabies Vaccine] voluntarily from all international markets, including Vietnam in late 2015 / early 2016 to meet our international quality requirements.

Further, we state that we do not have any information that Ministry of Health has banned Lyssavac or any Zydus product in Vietnam. The Company is not listed in the list of black listed Companies published by the Ministry of Health, Vietnam.”

Please bring the clarification from the Company to the notice of the members of the Exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For **CADILA HEALTHCARE LIMITED**



**UPEN H. SHAH**  
COMPANY SECRETARY